Research Article
The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures
Table 4
Comparisons of adverse events.
| | IV/SC group | Number (n) | Ratio of incidence (%) | Ratio of incidence in phase 3 (%) |
| | Teriparatide (daily) | 12 | 10 | 12–13 | | Teriparatide (weekly) | 10 | 28 | 30–50 | | Denosumab (biannually) | 4 | 11 | 12 | | Ibandronate (monthly) | 13 | 9 | 10 | | Alendronate (monthly) | 2 | 5 | 7 |
| | Oral group | Number (n) | Ratio of incidence (%) | Ratio of incidence in phase 3 (%) | | Alendronate (monthly) | 45 | 6.7 | 10 | | Minodronate (monthly) | 5 | 1.1 | Unknown | | SERM (daily) | 1 | 1.4 | Under 1 | | Risedronate (monthly) | 2 | 1.6 | 1–5 |
|
|
Phase 3: Japanese clinical trial final stage before approval; IV/SC: intravenous/subcutaneous.
|
